Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Cash from Operations (2016 - 2025)

Ultragenyx Pharmaceutical has reported Cash from Operations over the past 10 years, most recently at 99829000.0 for Q4 2025.

  • Quarterly Cash from Operations fell 25.86% to 99829000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 466000000.0 through Dec 2025, down 12.56% year-over-year, with the annual reading at 466000000.0 for FY2025, 12.56% down from the prior year.
  • Cash from Operations was 99829000.0 for Q4 2025 at Ultragenyx Pharmaceutical, down from 91423000.0 in the prior quarter.
  • Over five years, Cash from Operations peaked at 54344000.0 in Q4 2021 and troughed at 190727000.0 in Q1 2024.
  • The 5-year median for Cash from Operations is 93384000.0 (2022), against an average of 103708000.0.
  • Year-over-year, Cash from Operations tumbled 174.82% in 2021 and then surged 43.16% in 2024.
  • A 5-year view of Cash from Operations shows it stood at 54344000.0 in 2021, then plummeted by 66.24% to 90342000.0 in 2022, then grew by 6.91% to 84098000.0 in 2023, then rose by 5.69% to 79315000.0 in 2024, then fell by 25.86% to 99829000.0 in 2025.
  • Per Business Quant, the three most recent readings for RARE's Cash from Operations are 99829000.0 (Q4 2025), 91423000.0 (Q3 2025), and 108273000.0 (Q2 2025).